U
CASC

UBS’s Cascadian Therapeutics, Inc. CASC Stock Holding History

UBS’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-317
Closed -$6K – 11079
2014
Q1 		$6K Hold
317
– – ﹤0.01% 9430
2013
Q4 		$3K Sell
317
-166
-34% -$1.86K ﹤0.01% 9924
2013
Q3 		$6K Buy
483
+333
+222% +$3.5K ﹤0.01% 9320
2013
Q2 		$1K Buy
+150
New +$1.93K ﹤0.01% 10079

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

UBS's CASC Position: Q3 2014 in Review

UBS increased its Cascadian Therapeutics, Inc. (CASC) stake by 89% in Q3 2014, buying an estimated $26.3K and bringing the position to 3,652 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #7067.

UBS first reported a position in CASC in Q2 2013 and has held it in 6 quarters since. The position peaked at $563K in Q1 2014. 86 funds tracked by Wall St. Rank hold CASC as of Q3 2014.

  • UBS held 3,652 shares of Cascadian Therapeutics, Inc. worth $42K as of Q3 2014.
  • UBS bought 1,722 Cascadian Therapeutics, Inc. shares in Q3 2014, an estimated $26.3K.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7067 holding.
  • UBS first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Cascadian Therapeutics, Inc. position peaked at $563K in Q1 2014.
  • 86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.